Patterns of Intervention Utilization Among School-Aged Children with Autism Spectrum Disorder: Findings from a Multi-Site Research Consortium.

Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101300021 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1750-9467 (Print) NLM ISO Abbreviation: Res Autism Spectr Disord Subsets: PubMed not MEDLINE

Original Publication: Amsterdam : Elsevier

When designing and interpreting results from clinical trials evaluating treatments for children on the autism spectrum, a complicating factor is that most children receive a range of concurrent treatments. Thus, it is important to better understand the types and hours of interventions that participants typically receive as part of standard of care, as well as to understand the child, family, and geographic factors that are associated with different patterns of service utilization. In this multi-site study, we interviewed 280 caregivers of 6-to-11-year-old school-aged children on the autism spectrum about the types and amounts of interventions their children received in the prior 6 weeks. Reported interventions were coded as " evidence-based practice" or " other interventions," reflecting the level of empirical support. Results indicated that children received a variety of interventions with varying levels of empirical evidence and a wide range of hours (0 to 79.3 hours/week). Children with higher autism symptom levels, living in particular states, and who identified as non-Hispanic received more evidence-based intervention hours. Higher parental education level related to more hours of other interventions. Children who were younger, had lower cognitive ability, and with higher autism symptom levels received a greater variety of interventions overall. Thus, based on our findings, it would seem prudent when designing clinical trials to take into consideration a variety of factors including autism symptom levels, age, cognitive ability, ethnicity, parent education and geographic location. Future research should continue to investigate the ethnic, racial, and socioeconomic influences on school-aged intervention services.
Competing Interests: Conflict of Interest The authors [AS, JK, SF, MSD, JIN, CN, SW, RB, SJ, KC, CS, AN, JD] declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Dr. Dawson is on the Scientific Advisory Boards of Janssen Research and Development, Akili Interactive, Inc, LabCorp, Inc, Roche Pharmaceutical Company, and Tris Pharma, and is a consultant to Apple, Gerson Lehrman Group, Guidepoint Global, Inc, and is CEO of DASIO, LLC. Dr. Dawson has stock interests in Neuvana, Inc. Dr. Dawson has the following patent No. 10,912,801 and patent applications: 62,757,234, 25,628,402, and 62,757,226. Dr. Dawson has developed technology, data, and/or products that have been licensed to Apple, Inc. and Cryocell, Inc. and Dawson and Duke University have benefited financially. James C. McPartland consults with Customer Value Partners, Bridgebio, Determined Health, and BlackThorn Therapeutics, has received research funding from Janssen Research and Development, serves on the Scientific Advisory Boards of Pastorus and Modern Clinics, and receives royalties from Guilford Press, Lambert, and Springer. Frederick Shic consults for Janssen Research and Development, Roche Pharmaceuticals, and BlackThorn Therapeutics.

Psychiatr Serv. 2011 Aug;62(8):975-8. (PMID: 21807842)
J Autism Dev Disord. 2021 Apr;51(4):1316-1330. (PMID: 32683545)
J Consult Clin Psychol. 1987 Feb;55(1):3-9. (PMID: 3571656)
Eur Neuropsychopharmacol. 2021 Jul;48:3-31. (PMID: 34158222)
Pediatrics. 2010 Jan;125(1):e17-23. (PMID: 19948568)
J Am Acad Child Adolesc Psychiatry. 2019 Sep;58(9):853-865. (PMID: 30768394)
Implement Sci. 2016 Oct 10;11(1):135. (PMID: 27724933)
Front Integr Neurosci. 2020 Apr 09;14:16. (PMID: 32346363)
Focus Autism Other Dev Disabl. 2013 Sep 1;28(3):138-146. (PMID: 24089593)
Autism. 2016 Jan;20(1):106-15. (PMID: 25948601)
J Appalach Health. 2020 Jan 26;2(1):25-40. (PMID: 35769534)
Pediatrics. 2020 Apr;145(Suppl 1):S35-S46. (PMID: 32238530)
Eur Neuropsychopharmacol. 2021 Jul;48:40-41. (PMID: 33731267)
J Autism Dev Disord. 2018 Sep;48(9):3086-3092. (PMID: 29654453)
J Spec Educ. 2014 Nov;48(3):167-179. (PMID: 25419002)
Autism. 2019 Jan;23(1):167-174. (PMID: 29126371)
Am Psychol. 2006 May-Jun;61(4):271-85. (PMID: 16719673)
Adm Policy Ment Health. 2012 Sep;39(5):365-73. (PMID: 21533846)
MMWR Surveill Summ. 2012 Mar 30;61(3):1-19. (PMID: 22456193)
J Dev Behav Pediatr. 2008 Jun;29(3):152-60. (PMID: 18349708)
Milbank Q. 2009 Jun;87(2):368-90. (PMID: 19523122)
Arch Pediatr Adolesc Med. 2011 Feb;165(2):141-6. (PMID: 21300654)
Health Aff (Millwood). 2017 Oct 1;36(10):1754-1761. (PMID: 28971920)
J Ment Health Res Intellect Disabil. 2018;11(2):111-123. (PMID: 30369999)
J Autism Dev Disord. 2009 May;39(5):693-705. (PMID: 19082876)
Health Serv Res. 2019 Aug;54(4):912-919. (PMID: 31132161)
Res Autism Spectr Disord. 2015 Sep 1;17:40-51. (PMID: 26366192)
Autism. 2020 Nov;24(8):2008-2020. (PMID: 32564619)
OTJR (Thorofare N J). 2017 Oct;37(4):218-226. (PMID: 28874097)
MMWR Surveill Summ. 2020 Mar 27;69(4):1-12. (PMID: 32214087)
J Clin Child Adolesc Psychol. 2019;48(sup1):S247-S268. (PMID: 29384389)
Int J MCH AIDS. 2015;3(2):159-67. (PMID: 27621995)

P50 HD103524 United States HD NICHD NIH HHS; P50 HD105351 United States HD NICHD NIH HHS; U19 MH108206 United States MH NIMH NIH HHS; UL1 TR001863 United States TR NCATS NIH HHS

Keywords: autism spectrum disorder; child characteristics; family characteristics; geographical location; intervention use

Date Created: 20220421 Latest Revision: 20240826

20240826

PMC9015686

10.1016/j.rasd.2022.101950

35444715